Reduce severe side effects of fluoropyrimidine (e.g. 5-FU) treatment by DPYD genotyping.

Fluoropyrimidines are widely used for the treatment of various solid tumors. The PGX-5FU StripAssay® identifies the most severe genetic variant in the dihydropyrimidine dehydrogenase (DPYD) gene whereas the newly launched PGX-5FU XL StripAssay® covers the four most clinically important variants with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020.

 

PGX-5FU & PGX-5FU XL

 

  • Fluoropyrimidines (5-Fluorouracil, Capecitabine and Tegafur) are frequently used in cancer therapy. However, some patients develop severe treatment-related toxicity.
  • A part of fluoropyrimidine-related toxicity arises due to impaired activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD) caused by genetic variants in the DPYD gene.
  • CPIC Guidelines recommend DPYD genotype-guided fluoropyrimidine dosing to increase patient safety.

Link to CPIC Guidelines

 

ProductREFUnit SizeIFUBrochure
PGX-5FU StripAssay®4-72020 tests

PDF

PDF

PGX-5FU XL StripAssay®4-78020 tests

PDF

PDF